These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 25586166)
1. Significance of apoptotic and non-apoptotic disseminated tumor cells in the bone marrow of patients with clinically localized prostate cancer. Todenhöfer T; Hennenlotter J; Faber F; Wallwiener D; Schilling D; Kühs U; Aufderklamm S; Bier S; Mischinger J; Gakis G; Fehm T; Stenzl A; Schwentner C Prostate; 2015 May; 75(6):637-45. PubMed ID: 25586166 [TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment. Köllermann J; Weikert S; Schostak M; Kempkensteffen C; Kleinschmidt K; Rau T; Pantel K J Clin Oncol; 2008 Oct; 26(30):4928-33. PubMed ID: 18794550 [TBL] [Abstract][Full Text] [Related]
3. Redefining micrometastasis in prostate cancer - a comparison of circulating prostate cells, bone marrow disseminated tumor cells and micrometastasis: Implications in determining local or systemic treatment for biochemical failure after radical prostatectomy. Murray NP; Reyes E; Tapia P; Badinez L; Orellana N; Fuentealba C; Olivares R; Porcell J; Dueñas R Int J Mol Med; 2012 Oct; 30(4):896-904. PubMed ID: 22825050 [TBL] [Abstract][Full Text] [Related]
4. Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer. Thomas C; Wiesner C; Melchior SW; Schmidt F; Gillitzer R; Thüroff JW; Pfitzenmaier J BJU Int; 2009 Jul; 104(1):29-34. PubMed ID: 19154451 [TBL] [Abstract][Full Text] [Related]
5. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients. Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488 [TBL] [Abstract][Full Text] [Related]
6. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy. Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734 [TBL] [Abstract][Full Text] [Related]
7. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495 [TBL] [Abstract][Full Text] [Related]
8. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300 [TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion. Quinn DI; Henshall SM; Brenner PC; Kooner R; Golovsky D; O'Neill GF; Turner JJ; Delprado W; Grygiel JJ; Sutherland RL; Stricker PD Cancer; 2003 Apr; 97(8):1884-93. PubMed ID: 12673714 [TBL] [Abstract][Full Text] [Related]
10. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer. Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441 [TBL] [Abstract][Full Text] [Related]
11. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score. Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502 [TBL] [Abstract][Full Text] [Related]
12. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence. Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255 [TBL] [Abstract][Full Text] [Related]
13. Presence or absence of a positive pathological margin outperforms any other margin-associated variable in predicting clinically relevant biochemical recurrence in Gleason 7 prostate cancer. Huang JG; Pedersen J; Hong MK; Harewood LM; Peters J; Costello AJ; Hovens CM; Corcoran NM BJU Int; 2013 May; 111(6):921-7. PubMed ID: 23350712 [TBL] [Abstract][Full Text] [Related]
14. Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy. Berg A; Berner A; Lilleby W; Bruland ØS; Fosså SD; Nesland JM; Kvalheim G Int J Cancer; 2007 Apr; 120(8):1603-9. PubMed ID: 17230512 [TBL] [Abstract][Full Text] [Related]
15. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. Amling CL; Blute ML; Bergstralh EJ; Seay TM; Slezak J; Zincke H J Urol; 2000 Jul; 164(1):101-5. PubMed ID: 10840432 [TBL] [Abstract][Full Text] [Related]
16. Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer. Naume B; Synnestvedt M; Falk RS; Wiedswang G; Weyde K; Risberg T; Kersten C; Mjaaland I; Vindi L; Sommer HH; Sætersdal AB; Rypdal MC; Bendigtsen Schirmer C; Wist EA; Borgen E J Clin Oncol; 2014 Dec; 32(34):3848-57. PubMed ID: 25366688 [TBL] [Abstract][Full Text] [Related]
17. Should we replace the Gleason score with the amount of high-grade prostate cancer? Vis AN; Roemeling S; Kranse R; Schröder FH; van der Kwast TH Eur Urol; 2007 Apr; 51(4):931-9. PubMed ID: 16935413 [TBL] [Abstract][Full Text] [Related]
18. Minimal impact of clinical stage on prostate cancer prognosis among contemporary patients with clinically localized disease. Reese AC; Cooperberg MR; Carroll PR J Urol; 2010 Jul; 184(1):114-9. PubMed ID: 20478578 [TBL] [Abstract][Full Text] [Related]
19. Disseminated tumor cells and their prognostic significance in nonmetastatic prostate cancer patients. Lilleby W; Stensvold A; Mills IG; Nesland JM Int J Cancer; 2013 Jul; 133(1):149-55. PubMed ID: 23280694 [TBL] [Abstract][Full Text] [Related]
20. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy. Khatami A; Hugosson J; Wang W; Damber JE Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]